Arcellx, Inc. (NASDAQ:ACLX) is Affinity Asset Advisors LLC’s 3rd Largest Position

Affinity Asset Advisors LLC boosted its position in shares of Arcellx, Inc. (NASDAQ:ACLX) by 6.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 425,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. Arcellx accounts for approximately 4.4% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 3rd largest position. Affinity Asset Advisors LLC owned 0.79% of Arcellx worth $32,593,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. FMR LLC boosted its position in shares of Arcellx by 22.8% during the fourth quarter. FMR LLC now owns 7,956,633 shares of the company’s stock valued at $610,194,000 after buying an additional 1,477,360 shares during the period. Vanguard Group Inc. grew its stake in Arcellx by 35.3% in the 4th quarter. Vanguard Group Inc. now owns 3,330,092 shares of the company’s stock worth $255,385,000 after acquiring an additional 867,996 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Arcellx during the fourth quarter worth approximately $10,016,000. Federated Hermes Inc. boosted its holdings in shares of Arcellx by 141.4% in the fourth quarter. Federated Hermes Inc. now owns 156,094 shares of the company’s stock valued at $11,971,000 after purchasing an additional 91,430 shares during the period. Finally, Renaissance Technologies LLC bought a new position in Arcellx in the fourth quarter worth approximately $3,765,000. 96.03% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Christopher Heery sold 10,155 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $63.79, for a total value of $647,787.45. Following the completion of the transaction, the insider now owns 37,486 shares in the company, valued at $2,391,231.94. This trade represents a 21.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kavita Patel sold 1,500 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $63.16, for a total value of $94,740.00. The disclosure for this sale can be found here. Insiders have sold a total of 54,455 shares of company stock worth $3,408,458 over the last 90 days. 6.24% of the stock is currently owned by corporate insiders.

Arcellx Trading Up 1.9 %

Shares of ACLX stock opened at $60.30 on Tuesday. Arcellx, Inc. has a twelve month low of $47.88 and a twelve month high of $107.37. The stock has a fifty day simple moving average of $65.27 and a two-hundred day simple moving average of $75.74. The stock has a market capitalization of $3.31 billion, a price-to-earnings ratio of -84.93 and a beta of 0.33.

Arcellx (NASDAQ:ACLX) last announced its earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The business had revenue of $15.27 million for the quarter, compared to analysts’ expectations of $27.42 million. Research analysts predict that Arcellx, Inc. will post -1.58 EPS for the current fiscal year.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).